Comparing concurrent and sequential chemotherapy with radiation for breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical research aims to determine the effectiveness of concurrent chemotherapy and radiation therapy compared to sequential chemotherapy followed by radiation therapy in patients with stage IIB-III breast cancer. The study will evaluate disease-free survival rates, the impact on quality of life, side effects such as lymphoedema, and the financial costs associated with each treatment approach. Participants will receive standard chemotherapy and radiation therapy over a specified period, with follow-up assessments to monitor outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Pathologically confirmed invasive breast cancer
2. Stage IIB-III invasive breast cancer (AJCC 8th edition)
3. Patients planned for adjuvant chemotherapy and adjuvant radiotherapy
4. Patients fit to receive adjuvant chemotherapy and radiotherapy
5. Age \> 18 years

Exclusion Criteria:

1. Hypersensitivity to taxanes
2. Patients receiving entire chemotherapy prior to surgery (neoadjuvant setting)
3. Unable or unwilling for regular follow up
4. Bilateral tumour needed RT to both sides
5. Patients planned for RT to oligometastatic sites
6. Unfavourable anatomical factors potentially leading to higher radiotherapy dose to heart and/or lungs (Exceeding the protocol specific mandatory dose constraints).
7. Pregnant patient

Where it's running

• Tata Memorial Centre
  Mumbai, Maharasthra, India Recruiting
• Homi Bhabha Cancer Hospital & Research Centre
  Vishkhapatnam, Andhra Pradesh, India Not yet recruiting
• Homi Bhabha Cancer Hospital and Research Centre
  New Chandigarh, Punjab, India Not yet recruiting
• Homi Bhabha Cancer Hospital, Sangrur
  Sangrur, Punjab, India Not yet recruiting
• Mahamana Pandit Madan Mohan Malviya Cancer Centre
  Varanasi, Uttar Pradesh, India Not yet recruiting

Study contacts

• Study coordinator: Tabassum Wadasadawala, MD, DNB Radiotherapy
• Email: drtabs.radonc@gmail.com
• Phone: (+91-22) 24177026

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment for early-stage HER2 low, hormone receptor positive breast cancer

  This study is testing whether a new treatment combining trastuzumab deruxtecan and anastrozole can help people with early-stage HER2 low, hormone receptor positive breast cancer do better than just using trastuzumab deruxtecan alone.

  Recruiting at 7 sites Phase 2 Jonsson Comprehensive Cancer Center · Fullerton, California and 8 other locations · NCT04553770

• Using elacestrant to treat ER+/HER2- breast cancer patients with ctDNA relapse

  This study is testing if a new drug called elacestrant can help women with ER-positive, HER2-negative breast cancer who have had a relapse, compared to their usual treatment.

  Recruiting at 113 sites Phase 3 European Organisation for Research and Treatment of Cancer - EORTC · Anderlecht and 112 other locations · NCT05512364

• 68Ga-FAPI PET/MRI imaging to see if it can track breast cancer response to chemotherapy

  This study tests whether a new imaging scan, 68Ga-FAPI PET/MRI, can show how well invasive breast cancer responds to neoadjuvant chemotherapy in adults.

  Recruiting at 8 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07899892

• 18F‑FES PET/CT to detect distant metastasis in low‑grade ER‑positive stage III breast cancer

  This test will see if 18F‑FES PET/CT can better find distant spread in people with low‑grade, estrogen receptor–positive stage III breast cancer.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT07314073

• Making organoids from breast tumors before and after neoadjuvant chemotherapy

  This project will test whether lab-grown mini-tumors (patient-derived organoids) and blood biomarkers can help predict who will have a complete response to neoadjuvant chemotherapy for invasive breast cancer.

  Recruiting Istituti Clinici Scientifici Maugeri SpA · Pavia, PV · NCT07260188

• Disappearing markers for daily breast radiation delivery

  This trial will test whether Magic Ink tattoos are as safe and remain visible as standard tattoo ink for women getting radiation after breast cancer surgery.

  Recruiting Barbara Ann Karmanos Cancer Institute · Detroit, Michigan · NCT07095114

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.